fluorouracil has been researched along with Metabolic Diseases in 4 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with potentially life-threatening toxicity following the administration of standard doses of 5-fluorouracil." | 8.82 | Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. ( Diasio, R; Ezzeldin, H, 2004) |
| "Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with potentially life-threatening toxicity following the administration of standard doses of 5-fluorouracil." | 4.82 | Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. ( Diasio, R; Ezzeldin, H, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ezzeldin, H | 1 |
| Diasio, R | 1 |
| Lazar, A | 1 |
| Mau-Holzmann, UA | 1 |
| Kolb, H | 1 |
| Reichenmiller, HE | 1 |
| Riess, O | 1 |
| Schömig, E | 1 |
| Lim, WT | 1 |
| McLeod, HL | 1 |
| Gear, EV | 1 |
2 reviews available for fluorouracil and Metabolic Diseases
| Article | Year |
|---|---|
Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
Topics: Antimetabolites, Antineoplastic; Diagnosis, Differential; Dihydropyrimidine Dehydrogenase Deficiency | 2004 |
Dobbins WO 3d,+DOBBINS WO III: Rectal biopsy. A review of its diagnostic usefulness.
Topics: Amyloidosis; Biopsy; Colitis, Ulcerative; Crohn Disease; Cystic Fibrosis; Cysts; Deficiency Diseases | 1968 |
2 other studies available for fluorouracil and Metabolic Diseases
| Article | Year |
|---|---|
Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cecal Neoplasms; Dihydropyrimidine Dehydrogenase Defic | 2004 |
Should screening for DPD deficiency be mandatory before 5-FU exposure?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2004 |